TRDA
Entrada Therapeutics, Inc.Company Information
- Company Name
- Entrada Therapeutics, Inc.
- CIK
- CIK0001689375
- Category
- Accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- TRDA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TRDA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-20
- Last sale
- 2026-09-09
- Shares purchased (TTM)
- 134,603
- Shares sold (TTM)
- 871,640
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 28,217,978
- Shares outstanding
- 42,221,665
- Ownership
- 66.83%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- -0.85%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 99 | 76 | 90 | 93 | 72 | 68 | 101 | 78 | 185 | 68 | 68 | 52 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest | 124 | 178 | 205 | 234 | 282 | 315 | 319 | 371 | 284 | 259 | 284 | 302 | ||||||
| Restricted Cash Current | 0 | 0 | 1 | - | - | - | 0 | - | - | - | - | - | ||||||
| Contract With Customer Receivable After Allowance For Credit Loss | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 3 | 8 | 78 | 6 | 5 | ||||||
| Prepaid Expense And Other Assets Current | 9 | 11 | 9 | 10 | 14 | 19 | 16 | 13 | 12 | 9 | 12 | 24 | ||||||
| Assets Current | 233 | 267 | 306 | 338 | 369 | 403 | 440 | 465 | 490 | 414 | 370 | 383 | ||||||
| Property Plant And Equipment Net | 6 | 7 | 7 | 8 | 10 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | ||||||
| Restricted Cash Noncurrent | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Operating Lease Right Of Use Asset | 57 | 59 | 60 | 62 | 66 | 68 | 71 | 74 | 76 | 79 | 81 | 84 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 3 | 3 | ||||||
| Assets | 299 | 336 | 377 | 413 | 449 | 486 | 526 | 555 | 582 | 511 | 469 | 485 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 3 | 2 | 3 | 2 | 2 | 4 | 1 | 2 | 3 | 3 | 1 | ||||||
| Accrued Liabilities Current | 13 | 12 | 18 | 16 | 12 | 8 | 13 | 13 | 11 | 9 | 11 | 10 | ||||||
| Taxes Payable Current | - | - | 0 | 1 | 0 | 1 | 1 | 2 | 4 | 6 | 4 | - | ||||||
| Operating Lease Liability Current | 4 | 4 | 4 | 4 | 5 | 7 | 8 | 8 | 9 | 8 | 8 | 7 | ||||||
| Deferred Revenue Current | 0 | 0 | 0 | 0 | 1 | 1 | 14 | 46 | 60 | 148 | 132 | 148 | ||||||
| Liabilities Current | 21 | 19 | 24 | 24 | 20 | 18 | 39 | 71 | 86 | 174 | 159 | 165 | ||||||
| Operating Lease Liability Noncurrent | 44 | 45 | 47 | 48 | 49 | 50 | 52 | 54 | 56 | 58 | 60 | 62 | ||||||
| Deferred Revenue | - | - | 0 | 0 | 0 | 0 | 7 | 8 | 10 | 9 | 8 | 11 | ||||||
| Liabilities | 65 | 65 | 71 | 72 | 69 | 69 | 98 | 132 | 152 | 241 | 227 | 238 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 589 | 583 | 579 | 574 | 569 | 564 | 558 | 552 | 547 | 441 | 437 | 433 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 1 | 1 | 0 | 0 | -0 | 1 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -356 | -313 | -273 | -234 | -190 | -147 | -129 | -130 | -116 | -171 | -195 | -185 | ||||||
| Stockholders Equity | 233 | 271 | 306 | 341 | 380 | 417 | 429 | 422 | 430 | 269 | 242 | 247 | ||||||
| Liabilities And Stockholders Equity | 299 | 336 | 377 | 413 | 449 | 486 | 526 | 555 | 582 | 511 | 469 | 485 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 39 | 39 | 38 | 38 | 38 | 38 | 38 | 37 | 37 | 34 | 33 | 33 | ||||||
| Shares Outstanding | 39 | 39 | 38 | 38 | 38 | 38 | 38 | 37 | 37 | 34 | 33 | 33 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEntrada Therapeutics, Inc. (TRDA) — SEC Financial Statements & Analysis
Entrada Therapeutics, Inc. (TRDA) is a pharmaceutical preparations company, incorporated in DE. Entrada Therapeutics, Inc. trades on Nasdaq as: TRDA. Entrada Therapeutics, Inc. (TRDA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Entrada Therapeutics, Inc. carries a market cap of $310.75M, a P/E ratio of -1.87x, a P/B ratio of 1.33x, a P/S ratio of 66.31x, an enterprise value of $208.18M, and an EV/EBITDA multiple of -1.20x. On profitability, it posts an operating margin of -3767.07%, a net margin of -3537.73%, a Return on Equity (ROE) of -54.09%, a Return on Assets (ROA) of -44.35%, and a Return on Invested Capital (ROIC) of -81.05%. Per share, it reports EPS of $-3.93, diluted EPS of $-3.93, free cash flow per share of $-3.20, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -94.10% year-over-year, net income growth of 126.00% year-over-year, and EPS growth of 121.27% year-over-year. On the balance sheet, it maintains a current ratio of 10.89x, a quick ratio of 10.47x, working capital of $211.33M, a debt-to-equity ratio of 0.28x, a debt ratio of 0.22, free cash flow of $-135.11M (TTM), and net debt of $-102.57M. Figures sourced from SEC EDGAR.
- Market Cap
- $310.75M
- P/E TTM
- -1.87x
- EPS TTM
- $-3.93
- P/B TTM
- 1.33x
- ROE TTM
- -54.09%
- ROA TTM
- -44.35%
- Debt To Equity
- 0.28x
- Free Cash Flow TTM
- $-135.11M
- Net Revenue TTM Growth 1Y
- -94.10%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Entrada Therapeutics, Inc. in?
Entrada Therapeutics, Inc. (TRDA) operates in the Pharmaceutical Preparations industry.
What exchange does TRDA trade on?
Entrada Therapeutics, Inc. (TRDA) trades on the Nasdaq.
Where is Entrada Therapeutics, Inc. incorporated?
Entrada Therapeutics, Inc. is incorporated in DE.
When was Entrada Therapeutics, Inc. (TRDA)'s most recent SEC filing?
Entrada Therapeutics, Inc. (TRDA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is TRDA's market cap?
Entrada Therapeutics, Inc. (TRDA) has a market capitalization of $310.75M as of 2026-06-30.
What is TRDA's EPS (earnings per share)?
Entrada Therapeutics, Inc. (TRDA)'s trailing twelve month EPS is $-3.93 as of 2026-06-30.
What is TRDA's ROE (return on equity)?
Entrada Therapeutics, Inc. (TRDA)'s trailing twelve month Return on Equity (ROE) is -54.09% as of 2026-06-30.
What is TRDA's ROA (return on assets)?
Entrada Therapeutics, Inc. (TRDA)'s trailing twelve month Return on Assets (ROA) is -44.35% as of 2026-06-30.
What is TRDA's ROIC (return on invested capital)?
Entrada Therapeutics, Inc. (TRDA)'s trailing twelve month Return on Invested Capital (ROIC) is -81.05% as of 2026-06-30.
What is TRDA's EV/EBITDA?
Entrada Therapeutics, Inc. (TRDA)'s trailing twelve month EV/EBITDA is -1.20x as of 2026-06-30.